Evidence map›Paper›PMID 38097874›Full record

ArticleBrain tumor pathology2024

FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma.

Sofian Al Shboul, Shelagh Boyle, Ashita Singh, Tareq Saleh, Moath Alrjoub, Ola Abu Al Karsaneh, Amel Mryyian, Rand Dawoud, Sinem Gul, Shaden Abu Baker and 3 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Brain tumor pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Sofian Al ShboulDepartment of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan. sofian@hu.edu.jo.ORCID http://orcid.org/0000-0002-0455-4380
Shelagh BoyleMRC Human Genetics Unit, Institute of Genetics and Cancer, The University of Edinburgh, Crewe Road, Edinburgh, EH4 2XU, UK.
Ashita SinghInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, Scotland, UK.
Tareq SalehDepartment of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan.
Moath AlrjoubDepartment of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Ola Abu Al KarsanehDepartment of Microbiology, Pathology, and Forensic Medicine, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan.
Amel MryyianDepartment of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan.
Rand DawoudDepartment of Pharmacology and Public Health, Faculty of Medicine, The Hashemite University, Zarqa, 13133, Jordan.
Sinem GulInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, Scotland, UK.
Shaden Abu BakerDepartment of Pathology and Microbiology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, 22110, Jordan.
Kathryn BallInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, Scotland, UK.
Ted HuppInstitute of Genetics and Cancer, University of Edinburgh, Edinburgh, EH4 2XR, Scotland, UK. ted.hupp@ed.ac.uk.
Paul M BrennanTranslational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. paul.brennan@ed.ac.uk.
Hashemite University · JOEdinburgh Cancer Research · GBJordan University of Science and Technology · JOEdinburgh Royal Infirmary · GBInstitute of Genetics and Cancer · GB

Funding

Hashemite University 418/84/2019Hashemite University 465/83/2019Hashemite University 738/54/2022Hashemite University 785/48/2022
6 · The paper itself

Abstract

Deletion of CDKN2A occurs in 50% of glioblastomas (GBM), and IFNA locus deletion in 25%. These genes reside closely on chromosome 9. We investigated whether CDKN2A and IFNA were co-deleted within the same heterogeneous tumour and their prognostic implications. We assessed CDKN2A and IFNA14 deletions in 45 glioma samples using an in-house three-colour FISH probe. We examined the correlation between p16

Indexed as

Cyclin-Dependent Kinase Inhibitor p16GlioblastomaGene DeletionHomozygoteHumansInterferon-alphaSequence DeletionCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16IFNA14 protein, humanInterferon-alphaCDKN2AFISHGlioblastomaIHCInterferon-alpha (IFNA)

Identifiers

PMID38097874
OpenAlexW4389729033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.